{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T00:00:18Z","timestamp":1784246418264,"version":"3.55.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,11,27]]},"DOI":"10.7759\/cureus.97905","type":"journal-article","created":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T08:28:08Z","timestamp":1764232088000},"source":"Crossref","is-referenced-by-count":0,"title":["Real-World Outcomes of Peri-Operative Chemotherapy With Fluorouracil, Leucovorin, Oxaliplatin, and Docetaxel in Upper Gastrointestinal Cancers: An Audit of Patients Diagnosed Between 2017 and 2020 at the Christie Hospital"],"prefix":"10.7759","author":[{"given":"Mariam","family":"Sabry","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yazan","family":"Mahmoud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yass","family":"Hatahet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rianne","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nour","family":"Ibrahim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660","article-title":"Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung H","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021, 71:209-49. 10.3322\/caac.21660","journal-title":"CA Cancer J Clin"},{"key":"ref2","unstructured":"Cancer registration statistics, England. 2017\r\n. (2017). Accessed: April 11, 2022: https:\/\/www.ons.gov.uk\/peoplepopulationandcommunity\/healthandsocialcare\/conditionsanddiseases\/bulletins\/cancerregistr...."},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.5732\/cjc.011.10390","article-title":"Epidemiologic differences in esophageal cancer between Asian and Western populations","volume":"31","author":"Zhang HZ","year":"2012","unstructured":"Zhang HZ, Jin GF, Shen HB. Epidemiologic differences in esophageal cancer between Asian and Western populations. Chin J Cancer. 2012, 31:281-6. 10.5732\/cjc.011.10390","journal-title":"Chin J Cancer"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2017.155","article-title":"Predicting the future burden of esophageal cancer by histological subtype: international trends in incidence up to 2030","volume":"112","author":"Arnold M","year":"2017","unstructured":"Arnold M, Laversanne M, Brown LM, Devesa SS, Bray F. Predicting the future burden of esophageal cancer by histological subtype: international trends in incidence up to 2030. Am J Gastroenterol. 2017, 112:1247-55. 10.1038\/ajg.2017.155","journal-title":"Am J Gastroenterol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1007\/s10620-018-5068-6","article-title":"Barrett's esophagus and esophageal adenocarcinoma: how common are they really?","volume":"63","author":"Thrift AP","year":"2018","unstructured":"Thrift AP. Barrett's esophagus and esophageal adenocarcinoma: how common are they really?. Dig Dis Sci. 2018, 63:1988-96. 10.1007\/s10620-018-5068-6","journal-title":"Dig Dis Sci"},{"key":"ref6","unstructured":"Cancer Research UK. Oesophageal cancer survival statistics. (2018). Accessed: April 3, 2022: https:\/\/www.cancerresearchuk.org\/health-professional\/cancer-statistics\/statistics-by-cancer-type\/oesophageal-cancer\/s...."},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.3892\/ijo.2015.2856","article-title":"Update on Epstein-Barr virus and gastric cancer (review)","volume":"46","author":"Shinozaki-Ushiku A","year":"2015","unstructured":"Shinozaki-Ushiku A, Kunita A, Fukayama M. Update on Epstein-Barr virus and gastric cancer (review). Int J Oncol. 2015, 46:1421-34. 10.3892\/ijo.2015.2856","journal-title":"Int J Oncol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2019-320234","article-title":"Is gastric cancer becoming a rare disease? A global assessment of predicted incidence trends to 2035","volume":"69","author":"Arnold M","year":"2020","unstructured":"Arnold M, Park JY, Camargo MC, Lunet N, Forman D, Soerjomataram I. Is gastric cancer becoming a rare disease? A global assessment of predicted incidence trends to 2035. Gut. 2020, 69:823-9. 10.1136\/gutjnl-2019-320234","journal-title":"Gut"},{"key":"ref9","unstructured":"Cancer Research UK. Stomach cancer survival statistics. (2018). Accessed: April 11, 2022: https:\/\/www.cancerresearchuk.org\/health-professional\/cancer-statistics\/statistics-by-cancer-type\/stomach-cancer\/survival."},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.mpmed.2019.02.005","article-title":"Barrett\u2019s oesophagus and oesophageal adenocarcinoma","volume":"47","author":"Januszewicz W","year":"2019","unstructured":"Januszewicz W, Fitzgerald RC. Barrett\u2019s oesophagus and oesophageal adenocarcinoma. Medicine (Abingdon). 2019, 47:275-85. 10.1016\/j.mpmed.2019.02.005","journal-title":"Medicine (Abingdon)"},{"key":"ref11","unstructured":"LCA Oesophageal and Gastric Cancer Clinical Guidelines. (2014). Accessed. April 12, 2022: https:\/\/rmpartners.nhs.uk\/wp-content\/uploads\/2017\/03\/LCA-OG-Cancer-Clinical-Guidelines-April-2014.pdf."},{"key":"ref12","article-title":"PET imaging in gastric carcinoma","author":"Kamimura K","year":"2011","unstructured":"Kamimura K, Nakajo M. PET imaging in gastric carcinoma. Management of Gastric Cancer. Ismaili N (ed): IntechOpen, London; 2011. 37-54."},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.4291\/wjgp.v5.i2.91","article-title":"Low grade dysplasia in Barrett\u2019s esophagus: Should we worry?","volume":"5","author":"Jagadesham VP","year":"2014","unstructured":"Jagadesham VP, Kelty CJ. Low grade dysplasia in Barrett\u2019s esophagus: Should we worry?. World J Gastrointest Pathophysiol. 2014, 5:91-9. 10.4291\/wjgp.v5.i2.91","journal-title":"World J Gastrointest Pathophysiol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.00721","article-title":"Performance status in cancer: not broken, but time for an upgrade?","volume":"38","author":"Scott JM","year":"2020","unstructured":"Scott JM, Stene G, Edvardsen E, Jones LW. Performance status in cancer: not broken, but time for an upgrade?. J Clin Oncol. 2020, 38:2824-9. 10.1200\/JCO.20.00721","journal-title":"J Clin Oncol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.5090\/kjtcs.2020.53.4.160","article-title":"The current evidence on neoadjuvant therapy for locally advanced esophageal squamous cell carcinoma","volume":"53","author":"Oh D","year":"2020","unstructured":"Oh D, Kim JH. The current evidence on neoadjuvant therapy for locally advanced esophageal squamous cell carcinoma. Korean J Thorac Cardiovasc Surg. 2020, 53:160-7. 10.5090\/kjtcs.2020.53.4.160","journal-title":"Korean J Thorac Cardiovasc Surg"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v16.i30.3793","article-title":"Neoadjuvant treatment of esophageal cancer","volume":"16","author":"Campbell NP","year":"2010","unstructured":"Campbell NP, Villaflor VM. Neoadjuvant treatment of esophageal cancer. World J Gastroenterol. 2010, 16:3793-803. 10.3748\/wjg.v16.i30.3793","journal-title":"World J Gastroenterol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.3978\/j.issn.2078-6891.2014.096","article-title":"Endoscopic options for early stage esophageal cancer","volume":"6","author":"Shah PM","year":"2015","unstructured":"Shah PM, Gerdes H. Endoscopic options for early stage esophageal cancer. J Gastrointest Oncol. 2015, 6:20-30. 10.3978\/j.issn.2078-6891.2014.096","journal-title":"J Gastrointest Oncol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.5772\/16855","article-title":"Lymph node dissection in gastric carcinoma","author":"Yuksel BC","year":"2011","unstructured":"Yuksel BC, Akturk OM, Ozel IH. Lymph node dissection in gastric carcinoma. Management of Gastric Cancer. Ismaili N (ed): IntechOpen, London; 2011. 10.5772\/16855"},{"key":"ref19","article-title":"Esophageal cancer treatment (PDQ\u00ae): Health Professional Version","author":".","year":"2025","unstructured":".. Esophageal cancer treatment (PDQ\u00ae): Health Professional Version. PDQ Cancer Information Summaries. National Cancer Institute, Bethesda, MD; 2025."},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa055531","article-title":"Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer","volume":"355","author":"Cunningham D","year":"2006","unstructured":"Cunningham D, Allum WH, Stenning SP, et al.. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 2006, 355:11-20. 10.1056\/NEJMoa055531","journal-title":"N Engl J Med"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa073149","article-title":"Capecitabine and oxaliplatin for advanced esophagogastric cancer","volume":"358","author":"Cunningham D","year":"2008","unstructured":"Cunningham D, Starling N, Rao S, et al.. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med. 2008, 358:36-46. 10.1056\/NEJMoa073149","journal-title":"N Engl J Med"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)32557-1","article-title":"Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel vs fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomized phase 2\/3 trial","volume":"393","author":"Al-Batran SE","year":"2019","unstructured":"Al-Batran SE, Homann N, Pauligk C, et al.. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel vs fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomized phase 2\/3 trial. Lancet. 2019, 393:1948-57. 10.1016\/S0140-6736(18)32557-1","journal-title":"Lancet"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.06.8429","article-title":"Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group","volume":"24","author":"Van Cutsem E","year":"2006","unstructured":"Van Cutsem E, Moiseyenko VM, Tjulandin S, et al.. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol. 2006, 24:4991-7. 10.1200\/JCO.2006.06.8429","journal-title":"J Clin Oncol"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1002\/onco.13836","article-title":"Early weight loss as a prognostic factor in patients with advanced gastric cancer: analyses from REGARD, RAINBOW, and RAINFALL phase III studies","volume":"26","author":"Mansoor W","year":"2021","unstructured":"Mansoor W, Roeland EJ, Chaudhry A, et al.. Early weight loss as a prognostic factor in patients with advanced gastric cancer: analyses from REGARD, RAINBOW, and RAINFALL phase III studies. Oncologist. 2021, 26:e1538-47. 10.1002\/onco.13836","journal-title":"Oncologist"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.3390\/curroncol29040221","article-title":"Prognostic relevance of weight and weight loss during multimodal therapy for oesophagogastric tumours","volume":"29","author":"Lorusso A","year":"2022","unstructured":"Lorusso A, Bichev D, H\u00f6gner A, et al.. Prognostic relevance of weight and weight loss during multimodal therapy for oesophagogastric tumours. Curr Oncol. 2022, 29:2706-19. 10.3390\/curroncol29040221","journal-title":"Curr Oncol"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2015.354","article-title":"The presence of lymphovascular and perineural infiltration after neoadjuvant therapy and oesophagectomy identifies patients at high risk for recurrence","volume":"113","author":"Lagarde SM","year":"2015","unstructured":"Lagarde SM, Phillips AW, Navidi M, Disep B, Immanuel A, Griffin SM. The presence of lymphovascular and perineural infiltration after neoadjuvant therapy and oesophagectomy identifies patients at high risk for recurrence. Br J Cancer. 2015, 113:1427-33. 10.1038\/bjc.2015.354","journal-title":"Br J Cancer"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-016-5416-8","article-title":"Prognostic significance of lymphovascular invasion for thoracic esophageal squamous cell carcinoma","volume":"23","author":"Wang S","year":"2016","unstructured":"Wang S, Chen X, Fan J, Lu L. Prognostic significance of lymphovascular invasion for thoracic esophageal squamous cell carcinoma. Ann Surg Oncol. 2016, 23:4101-9. 10.1245\/s10434-016-5416-8","journal-title":"Ann Surg Oncol"},{"key":"ref28","unstructured":"Grabsch HM, Mapstone NP, Novelli M. Standards and datasets for reporting cancers. Dataset for histopathological reporting of oesophageal and gastric carcinoma. (2019). Accessed. April 12, 2022: https:\/\/www.rcpath.org\/static\/f8b1ea3d-5529-4f85-984c8d4d8556e0b7\/068e9093-0aea-4316-bdd49771564784b9\/g006-dataset-fo...."},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1155\/2016\/7340180","article-title":"Prognostic value of perineural invasion in esophageal and esophagogastric junction carcinoma: a meta-analysis","volume":"2016","author":"Gao A","year":"2016","unstructured":"Gao A, Wang L, Li J, Li H, Han Y, Ma X, Sun Y. Prognostic value of perineural invasion in esophageal and esophagogastric junction carcinoma: a meta-analysis. Dis Markers. 2016, 2016:7340180. 10.1155\/2016\/7340180","journal-title":"Dis Markers"}],"updated-by":[{"DOI":"10.7759\/cureus.r227","type":"retraction","label":"Retraction","source":"retraction-watch","updated":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T00:00:00Z","timestamp":1776297600000},"record-id":"71571"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/431352-real-world-outcomes-of-peri-operative-chemotherapy-with-fluorouracil-leucovorin-oxaliplatin-and-docetaxel-in-upper-gastrointestinal-cancers-an-audit-of-patients-diagnosed-between-2017-and-2020-at-the-christie-hospital","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T08:28:11Z","timestamp":1764232091000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/431352-real-world-outcomes-of-peri-operative-chemotherapy-with-fluorouracil-leucovorin-oxaliplatin-and-docetaxel-in-upper-gastrointestinal-cancers-an-audit-of-patients-diagnosed-between-2017-and-2020-at-the-christie-hospital"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,27]]},"references-count":29,"URL":"https:\/\/doi.org\/10.7759\/cureus.97905","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11,27]]}}}